Cancer-induced cystatin C prevents complement-mediated synaptic loss through TREM2-mediated microglial phenotype regulation, reducing C1q/C3 deposition and excessive pruning. This is clinically important but probably secondary to plaque remodeling plus microglial state change rather than a distinct mechanism. Synaptic biomarkers are noisy and slower-moving than amyloid PD markers, making mechanism proof difficult in humans.
## Mechanistic Overview
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration starts from the claim that modulating TREM2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## **Molecular Mechanism and Rationale** The TREM2 (Triggering Receptor Expressed on Myeloid cells 2) signaling cascade represents a critical node in neuroinflammation regulation, with its dysfunction fundamentally altering astrocyte-microgli
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
TREM2BiomarkerNeuroinflammationneurodegeneration
Convergent signals
TREM2 recurs across 2 selected hypotheses with aligned directionality in biomarker, neuroinflammation.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
1/11
dimensions won
Synaptic protection via microglial/compl
11/11
dimensions won
TREM2-Dependent Astrocyte-Microglia Cros
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.58
0.82
Evidence
0.55
0.80
Novelty
0.50
0.65
Feasibility
0.60
0.68
Impact
0.65
0.73
Druggability
0.50
0.65
Safety
0.55
0.58
Competition
0.60
0.70
Data
0.55
0.85
Reproducible
0.52
0.52
KG Connect
0.50
0.91
Score Breakdown
Dimension
Synaptic protection via microg
TREM2-Dependent Astrocyte-Micr
Mechanistic
0.580
0.820
Evidence
0.550
0.800
Novelty
0.500
0.650
Feasibility
0.600
0.680
Impact
0.650
0.730
Druggability
0.500
0.650
Safety
0.550
0.580
Competition
0.600
0.700
Data
0.550
0.850
Reproducible
0.520
0.520
KG Connect
0.500
0.911
Evidence
Synaptic protection via microglial/complement normalization
No evidence citations yet
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
No evidence citations yet
Debate Excerpts
Synaptic protection via microglial/complement norm
# Critical Evaluation of Hypotheses: Cancer-Cystatin-C-TREM2 Pathway Beyond Amyloid
## Preliminary Methodological Concerns
Before evaluating individual hypotheses, several systemic issues constrain ...
Domain Expert
The key feasibility filter is the source paper itself. In the February 5, 2026 `Cell` paper, Li et al. report that peripheral cancer/CSPs reduced amyloid in `5xFAD` and `APP/PS1`, but “did not affect ...
Synthesizer
{"ranked_hypotheses":[{"title":"Anti-inflammatory microglial reprogramming via cystatin-C/TREM2 axis","description":"Systemic tumors secrete cystatin C which crosses the BBB via LRP1 and engages TREM2...
TREM2-Dependent Astrocyte-Microglia Cross-talk in
6 rounds · quality: 0.95
Theorist
# Analysis of TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
## Mechanistic Evaluation
The hypothesis presents a sophisticated model of TREM2-mediated neuroimmune crosstalk wi...
Skeptic
# Critical Evaluation: TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
## Weakest Assumptions of the Hypothesis
### 1. **Exclusive Microglial Expression of TREM2**
The hypothes...
Domain Expert
# Translational Feasibility Assessment: TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
## Executive Summary
The hypothesis integrates well-established microglial biology with ...
Theorist
# THEORIST — Round 4 — RESPONSE TO SKEPTIC
## Addressing the Major Critiques
I appreciate the careful deconstruction of my hypothesis. The skeptic raises two substantive objections that deserve di...